PRMA Insights: The Roadmap to Pricing and Reimbursement Success

Scope of the metastatic breast cancer report

This Insights report is underpinned by comprehensive secondary research, experienced-based insight and validation by payors, and key opinion leaders, across the seven major markets:

In-depth coverage on the following subpopulations:

HER2+

HER2-

ER+

TNBC

 

Reporting of the regulatory nominations and key supporting data for the following targeted therapies:

Avastin

Herceptin

Ixempra

Tyverb/Tykerb

 

Reporting of key supporting data for:

Hormonal therapies

Chemotherapies

 

The current P&R landscape for metastatic breast cancer in the top seven major pharmaceutical markets:

US

UK

France

Germany

Spain

Italy

Japan

 

Reviews of metastatic breast cancer clinical guidelines as published by:

NCCN

ESMO

NICE

St Gallen

Japan Breast Cancer Society

 

Comprehensive review and assessment of pricing and reimbursment and HTA decisions for the molecularly targeted therapeutics and immunotherapies for metastatic breast cancer across all lines of therapy.

The assessments of over 30 HTA and pricing and reimbursement decisions recently made in metastatic breast cancer by the following bodies:

AIFA	CEPS	CMS	DGFPS	G-BA	InEK	IQWiG
MHLW	NICE	SMC	TC	UVEF

Find out more about the metastatic breast cancer report:

The report delivers         Scope of the report        Authors of the report